S100A9 and myocardial infarction: The role of targeted, short-term S100A9 inhibition on left ventricular systolic performance in an experimental model of myocardial infarction revealed that three days of inhibition of S100A9 during the acute inflammatory phase significantly modulates cardiac proteome changes in ways that favor myocardial recovery and repair processes.